Lydon Nicholas 4
4 · Blueprint Medicines Corp · Filed May 25, 2022
Insider Transaction Report
Form 4
Lydon Nicholas
Director
Transactions
- Exercise/Conversion
Stock Option (Right to Buy)
2022-05-23−10,909→ 0 totalExercise: $19.53Exp: 2026-06-23→ Common Stock (10,909 underlying) - Exercise/Conversion
Common Stock
2022-05-23$19.53/sh+10,909$213,053→ 50,584 total
Footnotes (1)
- [F1]This option was granted on June 23, 2016 and is fully vested.